Yahoo Web Search

Search results

1. People also ask

   Will Moderna regain sales growth in 2025?

   • Moderna said it expects to return to sales growth in 2025 with the help of new vaccines and break even the following year. The Cambridge, Massachusetts company forecast $4 billion in revenue next year from sales of its COVID and respiratory syncytial virus (RSV) vaccines.

   Moderna reins in 2023 COVID vaccine forecast, shares tumble

   www.reuters.com/business/healthcare-pharmaceuticals/moderna-revenue-tops-expectations-expects-return-sales-growth-2025-2023-11-02/

   See all results for this question

   How much will Moderna make in 2024?

   • Moderna continues to project approximately $4 billion in product sales in 2024, mostly in the second half of the year, primarily due to COVID-19 vaccine sales and the launch of its RSV vaccine. The Company anticipates returning to organic sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment.

   Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. M…

   finance.yahoo.com/news/moderna-provides-business-pipeline-updates-120000510.html

   See all results for this question

   How will Moderna perform in 2025?

   • The Company anticipates returning to organic sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment. Moderna expects numerous product milestones in 2024 and 2025 across its vaccines and therapeutics portfolio. Moderna is a leader in the creation of the field of mRNA medicine.

   Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. M…

   finance.yahoo.com/news/moderna-provides-business-pipeline-updates-120000510.html

   See all results for this question

   Will Moderna break even in 2023?

   • Moderna on Thursday said it expected 2023 revenue of at least $6 billion, a decline reflecting weaker demand for COVID-19 vaccines this year, but that it would return to sales growth in 2025 and break even the following year. Shares in the company fell 3% in premarket trading on Thursday.

   Moderna revenue tops expectations, expects to return to sales growth i…

   finance.yahoo.com/news/moderna-revenue-tops-expectations-expects-103000731.html

   See all results for this question

   Why did Moderna stock drop 8% in 2023?

   • Nov 2 (Reuters) - Moderna (MRNA.O) on Thursday said its 2023 sales would only hit the low end of its $6 billion to $8 billion forecast, reflecting weaker demand for COVID-19 vaccines, and its shares slumped 8%. The vaccine maker also pushed back to 2025 the launch of its flu shot, which it had previously said it expected to be available in 2024.

   Moderna reins in 2023 COVID vaccine forecast, shares tumble

   www.reuters.com/business/healthcare-pharmaceuticals/moderna-revenue-tops-expectations-expects-return-sales-growth-2025-2023-11-02/

   See all results for this question

   How much money does Moderna make a year?

   • The company reported third-quarter sales of $1.8 billion, topping analysts' estimates of $1.32 billion, according to LSEG data. Moderna's COVID-19 vaccine is its lone marketed product. Some $900 million of its quarterly revenue came from the U.S. and $800 million from international sales.

   Moderna revenue tops expectations, expects to return to sales growth i…

   finance.yahoo.com/news/moderna-revenue-tops-expectations-expects-103000731.html

   See all results for this question

2. investors.modernatx.com › news › news-detailsModerna Provides Business and Pipeline Updates at 42nd Annual ...

   investors.modernatx.com › news › news-details

   • Cached

   Jan 8, 2024 · Company reiterates 2024 expected product sales of approximately $4 billion, planned return to sales growth in 2025 and expectation to break even in 2026 through product launches and disciplined investment. Company highlights nine late-stage programs with anticipated milestones in 2024 and 2025

3. www.reuters.com › business › healthcareModerna reins in 2023 COVID vaccine forecast, shares tumble

   www.reuters.com › business › healthcare

   Nov 2, 2023 · Moderna said it expects to return to sales growth in 2025 with the help of new vaccines and break even the following year. The Cambridge, Massachusetts company forecast $4 billion in revenue...

4. www.reuters.com › business › healthcareModerna forecasts lower sales next year, shares near four ...

   www.reuters.com › business › healthcare

   Sep 12, 2024 · Sept 12 (Reuters) - Moderna (MRNA.O) pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its...

5. news.modernatx.com › news › news-detailsModerna Reports Third Quarter 2023 Financial Results and ...

   news.modernatx.com › news › news-details

   • Cached

   Nov 2, 2023 · In 2025, the Company expects to return to organic sales growth. The Company is projecting cost of sales as a percentage of sales to be approximately 35% in 2024, which is expected to improve with sales increasing in 2025.

6. finance.yahoo.com › news › moderna-provides-businessModerna Provides Business and Pipeline Updates at 42nd Annual ...

   finance.yahoo.com › news › moderna-provides-business

   Jan 8, 2024 · The Company anticipates returning to organic sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment.

7. investors.modernatx.com › news › news-detailsModerna Reports Fourth Quarter and Fiscal Year 2023 Financial ...

   investors.modernatx.com › news › news-details

   • Cached

   Feb 22, 2024 · Moderna took specific actions in 2023 to transition to a seasonal endemic market including the resizing of its manufacturing footprint to improve cash flow, the flattening of its commercial structure to drive sales execution, and the focusing of its investments toward near-term growth drivers.

8. finance.yahoo.com › news › moderna-revenue-topsModerna revenue tops expectations, expects to return to sales ...

   finance.yahoo.com › news › moderna-revenue-tops

   • Cached

   Nov 2, 2023 · Moderna on Thursday said it expected 2023 revenue of at least $6 billion, a decline reflecting weaker demand for COVID-19 vaccines this year, but that it would return to sales growth in...